搜尋





搜尋





市場行情
/
股票
/
nasdaq-rnaz
/

Transcode Therapeutics Inc

RNAZ

添加自選

7.650USD

+1.440+23.19%

收盤 07/01, 16:00（美東）報價延遲15分鐘

7.01M總市值

虧損本益比TTM

Transcode Therapeutics Inc

7.650

+1.440+23.19%

概覽

財務

分析

公司

查看詳細走勢圖

TradingKey 图表

盤中分時

1分

30分

1小時

日k

週k

月k

日k

今天

+23.19%

5天

+57.57%

1月

+48.83%

6月

+12.01%

今年開始到現在

+12.01%

1年

-1.92%

關鍵數據

6.250今開

7.970最高

68.78K成交量

虧損本益比TTM

--本益比動

--股利TTM

7.50%換手率

6.210昨收

6.250最低

344.98K成交額

虧損本益比靜

5.61市淨率

0.00%股息率 TTM

-47.38%ROA

20.99052週最高

2.76量比

-16.82M淨利潤

916.97K總股本

-3.7086每股盈餘TTM

1.32Beta

-757.04%ROE

5.01052週最低

27.70%振幅

--毛利率

7.01M總市值

2.98回報/風險

5.87%風險率

TradingKey 股票評分

由於缺少必要的數據，暫時無法對該公司進行評分

Transcode Therapeutics Inc新聞

即將為您帶來更多新聞，敬請期待。。。

TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

公司代碼RNAZ

公司Transcode Therapeutics Inc

CEOCalais (Philippe P)

網址https://www.transcodetherapeutics.com/